Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc

Executive Summary

Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.

You may also be interested in...



People In The News: Former Federal Officials On The Move; Changes At Aurinia, Neo, Mallinckrodt, Lilly, And More

Former FDA Commissioner and CMS Administrator Mark McClellan joins the Johnson & Johnson board; former CMS officials Larry Kocot, Mark Hamelburg and Thomas Hutchinson join law firm Epstein Becker & Green; ONCHIT head Farzad Mostashari heads to Brookings; Aurinia names Glickman acting CEO; more personnel moves in this month’s column.

Biopharma Tax Strategy Demystified: A Q&A With Ernst & Young

Several of this year’s biggest biopharma M&A deals provide significant tax benefits. “The Pink Sheet” brushes up on how multinational companies are managing tax considerations and examines more closely the core taxation issues for the industry.

No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials

Some of the biggest life science VCs are spending hundreds of millions of dollars to run the clinical trials of drugs owned by big drugmakers. But if the strategy works, they may have come up with a better way to diversify their portfolios in an era when long-term company-building isn’t paying off.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel